Senate Appropriations Chair Susan Collins has raised serious concerns about President Donald Trump’s intentions to allow political appointees to influence the distribution of health research grants, declaring such actions as a direct defiance of Congressional mandates.

Collins articulated her objections following revelations that President Trump plans to issue an executive order positioning White House budget director Russ Vought and NIH director Jay Bhattacharya on a panel tasked with deciding NIH grant allocations. This move, disclosed by administration officials who chose to remain anonymous, reportedly took shape during a meeting in the Oval Office last Friday.

This development comes on the heels of a temporary funding measure passed by Congress earlier this summer, which explicitly prohibits the White House from implementing any rules that would place political appointees in roles controlling federal grant approvals—or any similar maneuvers. “Any attempt to politicize grantmaking ... is contrary to congressional intent,” Collins stated, emphasizing that such actions would violate established policies that ensure grants are awarded based on scientific merit rather than political affiliations.

The proposal has also drawn criticism from other key lawmakers. Connecticut Representative Rosa DeLauro, a leading House Democrat, described the White House’s strategy as an attempt to manipulate federal funding to benefit allies and penalize opponents. Similarly, Senator Patty Murray of Washington warned of the potential dangers such politicization could pose to critical health studies, including those focused on cancer and Alzheimer’s disease, where a politically motivated appointee could reject important research without any scientific justification.

The Office of Management and Budget, under Trump’s directive, would play a significant role in this new grant-awarding process, a decision Collins strongly opposes. She argues that involving the OMB in such decisions “undermines the long-standing principle that the government funds awards based on scientific need and merit.”

As the debate heats up, the response from other key figures in Congress will be crucial in determining how this conflict between the executive branch and legislative intent will unfold. At the time of reporting, House Appropriations Chair Tom Cole had not yet commented on the issue.

This contentious plan by the White House not only threatens to alter the landscape of federal grantmaking but also sets the stage for a potential clash over the separation of powers and the integrity of U.S. scientific research funding.